The INHBE knockout MCF-7 polyclonal cells are a CRISPR/Cas9-edited polyclonal population of MCF-7 human breast adenocarcinoma epithelial cells in which the INHBE gene has been disrupted. This pooled knockout model provides a heterogeneous cell population, avoiding the biases of clonal selection and enabling robust functional studies of inhibin beta E without single-cell isolation artifacts.
MCF-7 is a widely used estrogen receptor-positive cell line derived from the pleural effusion of a 69-year-old Caucasian female with metastatic breast adenocarcinoma. Classified as luminal A molecular subtype, MCF-7 cells retain epithelial characteristics and are a standard in vitro model for hormone-responsive breast cancer, facilitating investigation of estrogen signaling, tumorigenesis, and drug responsiveness.
INHBE encodes the inhibin beta E subunit, which homodimerizes to form activin E or heterodimerizes with inhibin alpha (INHA) to produce inhibin E. Activin E engages type II receptors ACVR2A and ACVR2B, which recruit and activate the type I receptor ACVR1B (ALK4). This triggers phosphorylation of SMAD2 and SMAD3, which then associate with SMAD4 and translocate to the nucleus to regulate transcription of target genes such as SERPINE1 and TGFBI. The pathway is modulated by upstream regulators including FOXO1, HNF4A, insulin, and TGF-beta, and is influenced by interacting factors like the co-receptor TGFBR3 (betaglycan) and inhibitory SMAD7.
Disruption of INHBE in MCF-7 cells eliminates activin E/inhibin E signaling, offering a powerful system to dissect TGF-beta superfamily functions in a luminal A breast cancer context. Given INHBE’s involvement in energy homeostasis, liver metabolism, and cell proliferation, this knockout model is particularly suited for studying metabolic reprogramming in breast cancer and the interplay between metabolism and oncogenic processes.
These polyclonal knockout cells are applicable in diverse assays, including western blotting for SMAD2 phosphorylation, RT-qPCR of TGF-beta target genes, proliferation (MTT/BrdU) and apoptosis (Annexin V) assays, transwell migration, immunofluorescence for SMAD2/3 nuclear localization, RNA-sequencing for transcriptomic profiling, and metabolic flux analysis (Seahorse). Typical research areas include breast cancer biology, epithelial-mesenchymal transition, drug resistance, and functional genomics. For further information or to discuss custom applications, contact Ascent Research.
